Eli Lilly and Company and Scorpion Therapeutics a private biotechnology company specializing in small molecule precision oncology therapies, have announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kα inhibitor program, STX-478. This cutting-edge compound is a once-daily oral, mutant-selective…
WuXi AppTec Joins the Pharmaceutical Supply Chain Initiative to Strengthen Responsible Practices and Supply Chain Resilience Pharmaceutical Supply WuXi AppTec, a global leader providing comprehensive research, development, and manufacturing services to the pharmaceutical and life sciences industries, has announced its…
Regenerative Medicine Revolutionary Technologies Behind the Innovation Bio-Techne a renowned global leader in life science tools and reagents, has unveiled an impressive expansion to its R&D Systems AI-engineered designer protein portfolio. This latest development reflects Bio-Techne’s commitment to driving innovation…
HUB Organoids Merck Completes Acquisition of HUB Organoids Holding B.V., Expanding Next-Generation Biology Portfolio Merck, a global leader in science and technology, has finalized its acquisition of HUB Organoids Holding B.V. (HUB) after receiving regulatory approvals and meeting customary closing…
Trispecific WuXi Biologics a globally recognized Contract Research, Development, and Manufacturing Organization (CRDMO), has announced a groundbreaking partnership with Candid Therapeutics, Inc. (“Candid”). Candid is a clinical-stage biotechnology firm aiming to lead advancements in T-cell engager therapies for autoimmune and…
HIV Testing WHO Launches Guideline Development Group to Establish New HIV Prevention and Testing Standards for Lenacapavir The World Health Organization (WHO) has announced the formation of a new Guideline Development Group (GDG) tasked with creating updated guidelines for the…
Revolution Medicines, a clinical-stage oncology company focused on developing targeted therapies for patients with RAS-addicted cancers, recently announced the successful closing of its upsized underwritten public offering. The offering comprised 16,576,088 shares of common stock, priced at $46.00 per share,…
Heart Disease: The Importance of Regular Health Screenings Care Access, a leading health Heart Disease and research company, is bringing its Heart & Kidney Health Screening initiative to Pearland, Texas. This effort aims to raise awareness about critical health risk…
Amid the growing global shortage of Pegasys® (peginterferon alfa-2a), PharmaEssentia (TWSE: 6446), a global biopharmaceutical company, is reaffirming its steadfast commitment to ensuring robust and reliable access to critical interferon therapies. The company’s response comes at a time when the…
WuXi AppTec Recognized for Its Continued Commitment to Environmental, Social, and Governance Excellence WuXi Biologics a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has proudly announced its inclusion in the 2024 Dow Jones Sustainability Indices (DJSI) for the…
The Future of Cancer Immunotherapy: Market Insights 2025-2029 The report titled “Cancer Immunotherapy Market 2025-2029 – Forecasts for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer, with Executive and Consultant Guides” has been added to ResearchAndMarkets.com’s offerings. It aims to shed…
WuXi Biologics a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has entered a service agreement with Sino Biopharm, an innovative R&D-driven pharmaceutical group in China, to develop a first-in-class monoclonal antibody (mAb) targeting an undisclosed area. Under this…